Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers

American Journal of Pathology

Volumn 148, Issue 5, 1996, Pages 1567-1576

  Krajewska, Maryla ^a   Krajewski, Stanislaw ^a   Epstein, Jonathan I ^b   Shabaik, Ahmed ^c   Sauvageot, Jurgita ^b   Song, Ki ^a   Kitada, Shinichi ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UCSD MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOPROTEIN; PROTEIN BAX;

ADENOCARCINOMA; ANTIBODY SPECIFICITY; APOPTOSIS; ARTICLE; CANCER GRADING; CELL DEATH; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER;

ADENOCARCINOMA; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; HUMANS; IMMUNE SERA; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM PROTEINS; PHENOTYPE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 0029919668     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Wingo PA, Tong T, Bolden S. Cancer statistics. CA-Cancer J Clin 1995, 45:8-30
2. Crawford ED, Eisenberger MA, McLeod DC, Spaulding J, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A control randomized trial of Leuprolide with and without flutamide in prostatic cancer N Engl J Med 1989, 321.419-424
3. Kyprianou N, Isaacs JT. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology 1988, 122:552-562
4. Berges RR, Vukanovic J, Epstein JI, CarMichael M, Cisek L, Johnson DE, Veltri RW, Walsh PC, Isaacs JT. Implication of the cell kinetic changes during the progression of human prostatic cancer Clin Cancer Res 1995, 1.473-480
5. Raghaven D. Non-hormone chemotherapy for prostate cancer: principles of treatment and application to the testing of new drugs. Semin Oncol 1988, 15:371-389
6. Isaacs JT: Advances and controversies in the study of programmed cell death/apoptosis in the development of and therapy for cancer Curr Opin Oncol 1994, 6.82-89
7. Reed JC. Bcl-2 and the regulation of programmed cell death J Cell Biol 1994, 124.1-6
8. Tsujimoto Y, Croce CM Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma Proc Natl Acad Sci USA 1986, 83:5214-5218
9. Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death Nature 1990, 348 334-336
10. Krajewski S, Tanaka S, Takayama S, Schibler MJ, Fenton W, Reed JC Investigations of the subcellular distribution of the bcl-2 oncoprotein: residence in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membranes Cancer Res 1993, 53: 4701-4714
11. Reed JC: Bcl-2: prevention of apoptosis as a mechanism of drug resistance Hematol Oncol Clin North Am 1995, 9.451-474
12. Raffo AJ, Perlman H, Chen M-W, Day ML, Streitman JS, Buttyan R: Overexpression of bcl-2 protects prostate cancer cells from apoptosis in vitro and confers resistance to androgen depletion in vivo. Cancer Res 1995, 55.4438-4445
13. Berchem GJ, Bosseler M, Sugars LY, Voeller HJ, Zeitlin S, Gelmann EP: Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells. Cancer Res 1995, 55:735-738
14. McDonnell TJ, Troncoso P, Brisbay SM, Logothetis C, Chung LWK, Hsieh J-T, Tu S-M, Campbell ML: Expression of the proto-oncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992, 52:6940-6944
15. Oltvai ZN, Korsmeyer SJ: Checkpoints of dueling dimers foil death wishes. Cell 1994, 79:189-192
16. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang H-G, Reed JC: Immunohistochemical determination of in vivo distribution of bax, a dominant inhibitor of bcl-2 Am J Pathol 1994, 145.1323-1333
17. Krajewski S, Krajewska M, Shabaik A, Wang H-G, Irie S, Fong L, Reed JC. Immunohistochemical analysis of in vivo patterns of Bcl-X expression Cancer Res 1994, 54 5501-5507
18. Krajewski S, Bodrug S, Krajewska M, Shabaik A, Gascoyne R, Berean K, Reed JC: Immunohistochemical analysis of Mcl-1 protein in human tissues: differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo. Am J Pathol 1995, 146:1309-1319
19. Shabaik AS, Krajewski S, Burgan A, Krajewska M, Reed JC: bcl-2 proto-oncogene expression in normal, hyperplastic, and neoplastic prostate tissue. J Urol Pathol 1994, 3.17-27
20. Reed J, Meister L, Cuddy M, Geyer C, Pleasure D: Differential expression of the bcl-2 proto-oncogene in neuroblastomas and other human neural tumors Cancer Res 1991, 51:6529-6538
21. Krajewski S, Blomvqvist C, Franssila K, Krajewska M, Wasenius V-M, Niskanen E, Reed JC Reduced expression of pro-apoptotic gene Bax is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma Cancer Res 1995, 55.4471-4478
22. Kahane H, Sharp JW, Shuman GB, Dasilva G, Epstein JI: Utilization of high molecular weight cytokeratin on prostate needle biopsies in an independent laboratory. Urology 1995, 45:981-986
23. Oltvai Z, Milliman C, Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 1993, 74:609-619
24. Sato T, Hanada M, Bodrug S, Irie S, Iwama N, Boise LH, Thompson CB, Golemis E, Fong L, Wang H-G, Reed JC: Interactions among members of the bcl-2 protein family analyzed with a yeast two-hybrid system Proc Natl Acad Sci USA 1994, 91:9238-9242
25. Yin XM, Oltvai ZN, Korsmeyer SJ. BH1 and BH2 domains of bcl-2 are required for inhibition of apoptosis and heterodimerization with bax. Nature 1994, 369 321-333
26. Hanada M, Aimé-Sempé C, Sato T, Reed JC: Structure-function analysis of bcl-2 protein, identification of conserved domains important for homodimerization with bcl-2 and heterodimerization with bax. J Biol Chem 1995, 270:11962-11968
27. Bodrug SE, Aimé-Sempé C, Sato T, Krajewski S, Hanada M, Reed JC Biochemical and functional comparisons of Mcl-1 and Bcl-2 proteins: evidence for a novel mechanism of regulating Bcl-2 family protein function Cell Death Differ 1995, 2:173-182
28. Miyashita T, Reed JC: Bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs Cancer Res 1992, 52:5407-5411
29. L by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation Cell Growth Differ 1995, 6:363-370
30. Reynolds JE, Yang T, Qian L, Jenkinson JD, Zhou P, Eastman A, Craig RW: Mcl-1, a member of the Bcl-2 family, delays apoptosis induced by c-Myc overexpression in Chinese hamster ovary cells Cancer Res 1994, 54:6348-6352
31. González-Garcia M, Pérez-Ballestero R, Ding L, Duan L, Boise LH, Thompson CB, Núñez G: bcl-XL is the major bcl-X mRNA form expressed during murine development and its product localizes to mitochondria Development 1994, 120 3033-3042
32. Colombel M, Symmans F, Gil S, O'Toole KM, Chopin D, Benson M, Olsson CA, Korsmeyer S, Buttyan R. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers Am J Pathol 1993, 143:390-400
33. Segal NH, Cohen RJ, Haffejee Z, Savage N Bcl-2 proto-oncogene expression in prostate cancer and its relationship to the prostatic neuroendocrine cell. Arch Pathol Lab Med 1994, 118:616-618
34. Furuya Y, Krajewski S, Epstein JI, Reed JC, Isaacs JT: Enhanced expression of Bcl-2 and the progression of human and rodent prostatic cancers. Clin Cancer Res 1996 (in press)